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Abstract 
A bivalent dynamic covalent chemistry (DCC) system has been designed to selectively target members of the 
homodimeric glutathione-S-transferase (GST) enzyme family. The dynamic covalent libraries (DCLs) use 
aniline-catalysed acylhydrazone exchange between bivalent hydrazides and glutathione-conjugated aldehydes 
and the bis-hydrazides act as linkers to bridge between each glutathione binding site. The resultant DCLs were 
found to be compatible and highly responsive to templating with different GST isozymes, with the best results 
coming from the M and Schistosoma japonicum (Sj) class of GSTs, targets in cancer and tropical disease, 
respectively. The approach yielded compounds with selective, nanomolar affinity (Ki=61 nm for mGSTM1-1) 
and demonstrates that DCC can be used to simultaneously interrogate binding sites on different subunits of a 
dimeric protein. 
 
Introduction 
The use of dynamic covalent chemistry (DCC) to discover new binding motifs for protein targets is a growing 
area of research.
[1, 2] 
The DCC experiment involves an assembly of small molecules, termed a dynamic 
combinatorial library (DCL), in dynamic exchange through a reversible chemical reaction. In the presence of a 
target, such as a protein, the composition of the DCL will adjust to minimise the global free energy of the 
system. With suitable design parameters,
[3] 
this adaptive behaviour can favour the strongest binding protein 
component(s) at the expense of the weaker ones. The approach is thus distinct from conventional structure-
based drug design (SBDD) in that it requires no structural information and the synthesis event is accompanied 
by a qualitative binding assay. 
Pioneering work in biological DCC has featured protein targets that were necessarily well understood in terms 
of medicinal chemistry structure–activity relationships (SAR), with DCLs producing hit structures largely 
comprising known binding motifs.
[4]
 This was required to correlate the observed behaviour of DCLs in terms 
of amplifications with binding affinities. The future development of protein-directed DCC will depend on 
exploiting its complementarity to conventional methods,
[5]
 and applying it to targets that would challenge 
standard drug discovery approaches. We describe one such approach here, in which we use DCC to discover 
selective bivalent inhibitors of glutathione-S-transferase (GST) isozymes, including the most potent inhibitor 
to date for the M-class of this enzyme. 
The GSTs are a superfamily of enzymes responsible for conjugating the cellular thiol glutathione (GSH) to an 
array of endogenous and xenobiotic electrophiles (Scheme 1).
[6]
 The majority of GSTs exist as homodimers 
containing a conserved GSH binding site and a hydrophobic substrate binding region at the interface of the 
two monomers (Figure 1). As GSH conjugation is central to phase II metabolism, modulation of GST isozyme 
activity has been identified in a range of therapeutic areas, for example, oncology (multidrug resistance and 
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cell proliferation),
[7] 
asthma
[8] 
and inflammation.
[9] 
Parasite GSTs are also drug targets in tropical diseases, 
such as schistosomiasis and malaria, where they play a pivotal role in the life cycle of the parasite.
[10]
 
 
Scheme 1. GSTs and GSH conjugation. Electrophiles include, for example, xenobiotics, quinones (dopamine 
metabolism), prostaglandins, 4-hydroxyalkenals (lipid peroxidation), base propenals (DNA breakdown), 
chemotherapeutic agents. 
 
 
Figure 1. Structure of hGSTM1-1 that illustrates the H- and the G-sites (grey: monomer 1; yellow: monomer 
2; green: G-site; red: H-site); PDB ID: 1XWK; the Figure was generated by using PyMOL. 
 
The development of GST inhibitors is hampered by the plasticity of the H-site, which is large and has evolved 
to accept a range of small molecules in a variety of different conformations.
[11] 
Thus, despite the GSTs being 
amenable to X-ray crystallography, conventional SBDD methods have yielded relatively little in the way of 
potent, isoform-specific inhibitors. A notable exception is Atkins’ reports of bivalent inhibitors for the GSTα 
and π classes.[12] 
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As part of a multivalent strategy, non-selective GST inhibitors, such as ethacrynic acid, were appended to 
either end of a peptidic linker designed to span across the dimer interface. Using molecular modelling and 
split-and-pool combinatorial chemistry, the linker could be optimised to afford potent inhibitors with excellent 
selectivity between the GSTα and π isozymes (Figure 2). We have previously studied GST inhibition by DCC 
and discovered selective, monovalent G-site binders with low micromolar affinity.
[13]
 A DCC approach based 
around a bivalent strategy has exciting potential both for the discovery of more potent and selective GST 
inhibitors, as well as the development of new concepts for protein-directed DCC in general. The DCL would 
produce bivalent molecules that span relatively large surface areas across two protein subunits—a new 
development that contrasts with existing DCL systems directed by proteins. The DCL design would feature 
linking molecules and G-site binders, affording the opportunity to discover novel combinations with 
immediate qualitative information on their binding affinity. 
 
 
 
Figure 2. Atkins’ bivalent GSTA1-1 inhibitor, 1; KD=42 nm with 100-fold selectivity over GSTP1-1. 
 
Results 
We designed our DCL using aniline-catalysed acylhydrazone exchange
[14] 
as the reversible reaction. We have 
recently shown that aniline catalysis permits this reaction to be used at pH values greater than 6, enabling its 
use with biomolecular targets, such as the GSTs.
[13b, 15] 
The physicochemical and structural features of the 
acylhydrazone linkage have proven highly versatile in DCC, being exemplified across a range of systems and 
applications.
[16] 
Crucially, the quaternary structure of the dimeric enzyme remains intact in the presence of 
aniline, enabling ligand selection to take place from the DCL. We chose the three nitro-substituted 
benzaldehydes A1–A3 as our ligands. The compounds are analogues of the chloro-2,4-dintrobenzene (CDNB) 
structure, an archetypal weak-binding substrate of all GSTs.
[11a, 17] 
Our linkers L1–L4 were designed to have 
differing lengths and lipophilicity, thus maximising the opportunity to discriminate across the H-sites of 
different GST homodimers. 
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We constructed a DCL using the seven components A1–A3 and L1–L4 (Scheme 2), potentially forming a 
mixture of 24 homo- and hetero-bis-acylhydrazones (plus additional mono-acylhydrazones). Under reaction 
conditions with aniline (5 mm) in ammonium acetate buffer (0.1 m) containing 15 % by volume DMSO, pH 
6.4 at 25 °C, we observed equilibration in 6 h. Pleasingly, we were able to resolve the majority of bis-
acylhydrazone components using two HPLC columns in series (Figure 3). Identification of each peak was 
done by deconvolution in tandem with LC-MS analysis. 
 
 
 
 
Scheme 2. DCL design for bivalent inhibitor synthesis; GS=S-glutathionyl. Our DCL design uses the aniline-
catalysed reversible hydrazone formation between three aldehydes (A1–A3) and four bivalent hydrazides 
(L1–L4). 
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Figure 3. DCL consisting of linkers L1–L4 and aldehydes A1–A3. 
 
The DCL was then templated with four separate GST isozymes: mGSTM1-1, hGSTP1-1, SjGST and 
mGSTA4-4 (Figure 4). Best responses were obtained for the M and Sj isozymes, with the most notable 
amplification being product 3 (A1-L3-A1), amplified over 600 % by the M-class protein (Figure 5). Smaller 
amplifications were observed corresponding to hydrazones containing the hydrazide linker L2, the shortest of 
the linkers, and a single compound was amplified (2, >100 %) containing the longest linker, L4. For the 
SjGST isoform several peaks were amplified to a similar extent over the blank equilibrium. With the 
exception of A1-L3-A1, all of the other amplifications were due to acylhydrazones containing the hydrazide 
linker L2. 
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Figure 4. DCL targeted with four different GST isoforms: A, blank equilibrium. B, mGSTM1-1. C, hGSTP1-
1. D, sjGST. E, mGSTA4-4. The changes in DCL composition are represented in the bar chart as % 
Page 7 of 20 
differences of peak area over blank equilibrium. Error bars represent standard deviation over two experiments. 
The principal amplified peaks for mGSTM1-1 and SjGST are starred on the HPLC trace. 
 
The DCL was generally unresponsive to the mGSTA4-4 isozyme as a template, with some small 
amplifications being noted for components containing L2. The hGSTP1-1 isoform, by contrast, appeared to 
interfere with the DCL equilibrium for certain components. Bishydrazones containing two A1 units were 
degraded by the enzyme, with monohydrazones being favoured by the enzyme (see the Supporting 
Information). As a result, this isozyme was not used further in templating studies. 
With the amplified components identified, it was necessary to establish that the observed amplifications were 
due to a genuine templative effect from the GST active site. First, the addition of bovine serum albumin 
(BSA) to the DCL had little effect on the equilibrium composition (see the Supporting Information). Second, 
we examined the effect of adding GST inhibitors to the DCL mixture to see if amplification would be 
suppressed. This experiment is complicated in the case of the GSTs first by the lack of any potent inhibitors 
that are commercially available, and second by the propensity of such inhibitors that are known to bind in 
varying locations across the large H-site. A variety of non-selective, weakbinding inhibitors are known, 
however (Figure 5), and their effect on the DCL was examined. 
 
 
Figure 5. Known inhibitors of GSTs used to block the target’s binding pocket in DCL studies. 
 
Benzyl isothiocyanate (BITC) binds in the H-site of GSTs and is known to covalently modify the active 
site.
[18] 
Sulfasalazine binds in the H-site and is a competitive inhibitor. The crystal structure of sulfasalzine 
bound to hGSTP1-1 also shows that the pyridinyl ring binds in a shallow pocket on the surface of the 
protein.
[19]
 Ethacrynic acid is a non-specific inhibitor of GSTs widely used in GST studies, and binds in the H-
site. There is evidence that ethacrynic acid can bind in more than one orientation within this hydrophobic 
binding pocket.
[20]
 Similarly, the GSH-conjugate of CDNB, DNP–GSH, is believed to bind in a different 
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position to CDNB within the hydrophobic pocket.
[19]
 A final inhibitor, cibacron blue, which binds to the 
ligand in site of GSTs,
[19]
 was found to disrupt the background DCL equilibrium and could not be used as a 
control. 
Initial control experiments with smaller DCLs established that most of the inhibitors (at 200 μm) had little 
effect on the enzyme-templated DCL distribution. DNP–GSH, however, was effective in suppressing 
amplification in a dose-dependent fashion. Adding increasing amounts of DNP–GSH to the main DCL 
reduced the amplification of A1-L3-A1 (peak 3) and A1-L4-A1 (peak 2) in a dose-dependent fashion (see the 
Supporting Information). The amplification of peak numbers 11, 14, 17 and 21, corresponding to hydrazones 
not containing a terminal GSH residue, remained unaffected by the addition of DNP–GSH. This could 
indicate that the external inhibitor was blocking a GSH-binding interaction for the A1-containing ligands. To 
see if those compounds not containing GSH were binding in a different location within the enzyme, other 
inhibitors, such as ethacrynic acid and CDNB, were also added to the DCL. Unfortunately, the inhibitors 
eluted in the middle of the library of bis-acylhydrazones, making it very difficult to compare the GST-
templated library with the blank. 
To assess the biological activity of the amplified components we separately synthesised a selection of 
symmetrical bis-acylhydrazones for assay, to identify trends between amplification and binding affinity. The 
compounds A1-L1-A1, A1-L2-A1, A1-L3-A1 and A1-L4-A1containing the GS-tagged aldehyde A1 were 
strongly responsive to mGSTM1-1 in the DCL, and include the strongest amplified compound (A1-L3-A1). 
Compounds containing the L2 linker were also amplified to a lesser extent, whereas the remaining hydrazones 
containing L1and L4 were not selected in the DCL and could serve as useful negative controls. The 
compounds were tested in the chloro-2,4-dinitrobenzene (CDNB) assay, a standard protocol that measures the 
inhibition of GSH conjugation to CDNB by SNAr reaction.
[17] 
Table 1shows the IC50 data for a subset of 
symmetrical bis-acylhydrazones containing aldehyde component A1. 
 
Table 1. Table of IC50 data of DCL products with different GST isoforms measured by using the CDNB assay. 
Hydrazone IC50 [μm] 
  mGSTM1-1 hGSTP1-1 SjGST] mGSTA4-4 
A1-L1-A1 1.207 126.5 3.471 >100 
A1-L2-A1 0.337 11.81 0.252 >100 
A1-L3-A1 0.050 13.45 0.989 >100 
A1-L4-A1 0.413 0.356 1.800 >100 
aldehyde A1 341.7 ≥500 265.6 >500 
hydrazide L3 >500 >500 – – 
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The IC50 data correlated well with the amplifications observed in the DCL in the case of mGSTM1-1. The 
product with the greatest amplification was A1-L3-A1 (IC50=50 nm) an almost tenfold greater inhibition of 
GST activity relative to other hydrazone products. Gratifyingly, excellent isoform specificity was observed, 
with A1-L3-A1 showing approximately 20-fold greater inhibitory activity for mGSTM1-1 over SjGST and 
270-fold greater inhibitory activity over hGSTP1-1. Both A1-L2-A1 and A1-L4-A1 showed smaller 
amplifications in the DCL, and inhibited mGSTM1-1 at the sub-micromolar level. Compound A1-L1-A1 was 
reduced in concentration in the DCL and, accordingly, had the weakest activity at 1.2 μm. 
The data for SjGST was less well correlated between IC50 and amplification. Linker L1 was again selected 
against in the DCL, consistent with DCL distribution, and proved the weakest inhibitor (IC50=3.5 μm). 
Compound A1-L2-A1, however, was the most potent (IC50=0.25 μm) despite being amplified to a lesser 
extent than A1-L3-A1 (IC50=0.99 μm). Amplification is not always correlated to binding affinity, a 
phenomenon identified by Severin
[3a] 
and Sanders et al.
[3b, c] 
that arises from DCLs equilibrating to the global 
energy minimum. The dynamic exchange of DCL components means this global equilibration can be at the 
expense of any one local energy minima for a particular protein-binder complex, even the strongest one. For 
the SjGST-templated library, the majority of amplified peaks (peaks 4, 11, 14, 17 and 21) contained the L2 
linker as a common component. It is possible that competition for this shared building block reduced theA1-
L2-A1 amplification factor relative to A1-L3-A1 (peak 3), despite the stronger affinity of A1-L2-A1 for 
SjGST. 
The IC50 data for hGSTP1-1 could not be related to the DCL composition due to the lack of clear 
equilibration. The best inhibitor was A1-L4-A1 with an IC50 value of 0.36 μm, similar to that for mGSTM1-1 
(0.41 μm), and considerably more potent than the hydrazones containing shorter linkers. These data, taken 
with the amplification of monohydrazones in the hGSTP1-1 DCL, are consistent with the linkers L1–L3not 
being long enough to effectively span the two G-sites in hGSTP1-1.
[12]
 
The principle of multivalent binding was validated in general for all GST isoforms—there was a large 
increase in inhibitory activity when the two units of aldehyde A1 were connected by a linker, regardless of the 
length or shape of the linker, compared to the single aldehyde unit. This was strikingly illustrated for A1-L3-
A1, the most potent inhibitor of mGSTM1-1, whereby the two components A1 and L3 inhibited the enzyme at 
342 and 500 μm, respectively, and the assembled bis-acylhydrazone product was active at 50 nm (10 000-
times the potency of the isolated hydrazide linker). More specifically, varying the linker length and structure 
proved an effective strategy for discriminating between each GST isozyme;
[12b] 
the weak, non-specific 
inhibitor A1 became a potent, selective inhibitor when linked with L2 (SjGST), L3(GSTM1-1) and L4 
(GSTP1-1), respectively. 
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Figure 6. Assay of most potent compound, A1-L3-A1, with mGSTM1-1. A) Michaelis–Menten, and B) 
Lineweaver–Burk plots. The data best fit to a non-competitive (partial) equation. Standard errors are from 
three repeat experiments. C) ITC data: the top panel shows heat effects associated with the injection of ligand 
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into the cell containing GST. The lower panel shows the binding isotherm, generated from the integrated heats 
in the top panel, and the best fitted curves (see the Supporting Information for ITC data). 
 
The inhibition data for mGSTA4-4 shows that each of the hydrazone products had little effect on the enzyme 
activity, in line with the minimal templating effect of the enzyme on the DCL equilibrium. This made the 
mGSTA4-4 isoform an excellent negative control, demonstrating that changes in the distribution of hydrazone 
products was due to specific binding site interactions within the mGSTM1-1 isoform and not due to any non-
specific effects from the introduction of the hydrophobic protein to the DCL. 
The inhibition mechanism of the bivalent inhibitors for mGSTM1-1 was further characterised by using the 
CDNB competition assay and the three best binding bis-acylhydrazones A1-L2-A1, A1-L3-A1 and A1-L4-
A1. The data show that the hydrazones were non-competitive partial inhibitors of CDNB (Figure 6 a and b). 
The Ki values were in close agreement with IC50 measurements for A1-L3-A1 and A1-L4-A1, meeting the 
Cheng–Prusoff criteria of IC50=Ki for non-competitive inhibitors (Table 2).
[21]
 
 
Table 2. Binding data for DCL components with mGSTM1-1. 
Hydrazone IC50 [nm] Ki
[a]
 [nm] KD [nm] 
1. [a] Standard error shown for Ki data taken from three replicates. 
A1-L1-A1 1207 – – 
A1-L2-A1 337 646±80.7 525 
A1-L3-A1 50 61±4.1 107 
A1-L4-A1 413 634±23.8 – 
 
Isothermal calorimetry (ITC) was then used to determine the binding stoichiometry of the most potent 
compound A1-L3-A1. The results gave a binding stoichiometry of 0.4 with the GST monomer, supporting our 
hypothesis that the linker is binding across the dimeric GST structure (Figure 6 c). Finally, we examined the 
effect of the GS moiety on the aldehyde with respect to binding affinity. The symmetrical compounds A2-LX-
A2 and A3-LX-A3 were synthesised and their IC50 values determined by using the CDNB assay. As shown in 
Table 3, the removal of glutathione from the products resulted in a 100-fold decrease in inhibition for the 
longer linkers L3 and L4, demonstrating the importance of glutathione for binding affinity. The loss of 
glutathione for the shortest linker L2 was better tolerated, with a sixfold reduction in inhibition, suggesting 
that these shorter compounds were binding in a different mode to the longer linkers. Assaying A2-L2-A2, the 
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most potent bivalent inhibitor without glutathione, against CDNB again showed a non-competitive, partial 
inhibitor profile withKi=1.98(±0.47) μm. 
 
Table 3. IC50 data for homo-acylhydrazone linkers with mGSTM1-1.
[a]
 
Hydrazide 
linker 
A1-LX-A1 IC50 mGSTM1 
[μm] 
A2-LX-A2 IC50 mGSTM1 
[μm] 
A3-LX-A3 IC50 mGSTM1 
[μm] 
1. [a] Data were acquired by using the CDNB assay. 
aldehyde no 
linker 
341.7 – >500 
L1 1.21 – – 
L2 0.337 2.02 3.38 
L3 0.050 9.32 106.4 
L4 0.413 49.89 >100 
 
Discussion 
DCC has been used to identify novel bivalent inhibitors of GSTs, with the most potent compound (A1-L3-A1) 
inhibiting mGSTM1-1 with nanomolar activity and excellent isoform specificity over three other isoforms 
studied. Inhibition of the M-class of GSTs is relevant to oncology, where resistance to anticancer therapies has 
been correlated with altered expression levels of this enzyme (along with GSTP1).
[7, 22]
 Resistance 
mechanisms are twofold: GSTM1 can catalyse GSH conjugation to anticancer agents, and it can also down-
regulate the p38-MAPK pro-apoptotic pathway.
[23]
 
In this second mechanism, GSTM1 has been shown to bind to apoptosis signal-regulating kinase 1 (ASK1), 
which is a MAP kinase that activates both the JNK and p38 signalling pathways leading to apoptosis. GSTM1 
acts as an inhibitor of ASK1, which dissociates in response to cell stress resulting in the activation of ASK1. 
Literature reports of M-class GST inhibitors are sparse, with the natural product curcumin being the most 
potent compound described to date (IC50=0.3 μm for GSTM1-1).
[24]
 
To better understand the role of the selected linker L3 in spanning the two G-sites in the GSTM1-1 
homodimer, we constructed an overlay model based on the crystal structure of human glutathione-S-
transferase M1A-1A (PDB ID: 1XWK) containing the ligand DNP–GSH from Listowsky and co-workers.[25] 
The model shows clearly that the L3 linker can comfortably span the dimer interface without introducing any 
unfavourable contacts (Figure 7 a). The distance between the two GS moieties in the crystal structure (15.4 Å) 
and the equivalent in the model (15.5 Å) allows the GS moiety to nearly perfectly overlay in both binding 
sites within the dimer maintaining all contacts with the protein (Figure 7 b). The slightly longer L4 and the 
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shorter L2 and L1 linkers have correspondingly weaker affinity in their hydrazone adducts, requiring different 
linker conformation or protein movement to allow the GS moiety to maintain its binding mode in both G-sites. 
 
(a)  
(b)  
(c)  
Figure 7. a) and b) A1-L3-A1 overlaid onto GSTM1-1 crystal structure containing GS-DNB bound at each 
G-site. The protein surface across the dimer interface is shown with the two halves of the dimer coloured 
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yellow and red, respectively. The GS-DNB moiety of the crystal structure is shown in stick form with white 
carbons and the modelled A1-L3-A1 ligand is shown with cyan carbons. The ligand is seen to span the dimer 
interface whilst introducing no unfavourable contacts. C) Residue environment around the A1-L3-A1 ligand. 
All polar contacts to the protein come from the GS moiety and are identical to that found in the crystal 
structure. Polar contacts are indicated by black dashes. 
 
The presence of glutathione at the terminal of each linker was of particular importance for binding affinity for 
the longer linkers A1-L3-A1and A1-L4-A1. The glutathione was less important for linkers made from L2, 
with all hydrazones featuring L2 giving some amplification in the GST-templated DCLs. The activity of A1-
L2-A1 against the M, P and SjGST is somewhat surprising. The L2 linker should not be long enough to span 
the distance between the two G-sites without substantial distortion of the dimer structure, suggesting a 
different, possibly monovalent, binding mode. It should be noted, however, that the IC50 value of A1-L2-A1 
was very favourable in comparison to other monovalent inhibitors based on the A1 scaffold. Previous work 
from our laboratory has described acylhydrazone GST inhibitors formed from DCLs using A1 and 
monovalent acylhydrazides designed to explore the hydrophobic binding pocket.
[13b] 
The best of the 
compounds from that work had IC50 values of 50 μm for hGSTP1-1 and 20 μm for SjGST (2 and 3, Figure 8). 
This is a fivefold reduction in inhibition for hGSTP1-1 and a tenfold reduction for SjGST when compared to 
bivalent inhibitor A1-L2-A1. Compounds 2 and 3 showed little inhibitory effect against mGSTM1-1 with IC50 
values being greater than 100 μm. 
 
 
Figure 8. A1-L2-A1 binding data relative to monovalent hydrazones previously prepared. 
 
The monovalent acylhydrazones were competitive inhibitors of CDNB, and molecular docking studies 
indicated that they bound into the H-site. ITC was used to determine whether, due to the short linker length, 
two molecules of A1-L2-A1 were in fact binding to the GST dimer—one in each active site. Unfortunately, 
the results were inconclusive (n=0.7) with the measurements being complicated by gellation effects from the 
compound at higher concentration (see the Supporting Information). 
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Conclusion 
The versatility of DCC in discovering novel binding partners for proteins has been demonstrated, with the 
identification of a novel, isoform specific, bivalent inhibitor of mGSTM1-1. The success of the study rests on 
the ability of aniline to catalyse acylhydrazone exchange in the presence of proteins, without compromising 
tertiary and quaternary protein structure. The lead compound, A1-L3-A1, was amplified from a 24-membered 
library, and is the most potent (and selective) inhibitor described to date for the M-class of GSTs. DCC has a 
natural overlap with multivalent, fragment-type approaches to ligand discovery given that it is predicated on 
the assembly of small, weakly-binding fragments, in situ. Our study shows how this element of DCL design 
may be used very successfully in the discovery of potent enzyme inhibitors. We have also demonstrated that 
the addition of an external enzyme inhibitor to an equilibrating DCL can provide additional insights to simply 
switching amplification off. The large GST binding region interrogated by our DCLs enabled us to select a 
range of inhibitors that bind in different areas of the enzyme, and examine their effect (or lack of one) on the 
amplification of best-binding components. Finally, by designing DCLs to probe larger protein surface areas 
across two 28 kDa protein monomers, we have shown that the approach is suited to targets that are less 
tractable to conventional structure-based drug discovery methods. Future work will look to extrapolate these 
techniques to the study of protein–protein interactions. 
 
Experimental Section 
HPLC conditions for analysis of DCL libraries: Column, Luna 5μ C18(2), 50 mm×2.0 mm, and Luna 5μ 
C18(2), 30 mm×4.6 mm, in sequence; flow rate, 1 mL min−1; wavelength, 254 nm; temperature, 30 °C; 
gradient H2O/MeCN (0.01 % TFA) from 95 to 80 % over 15 min, then to 60 % over a further 15 min, and 
finally to 5 % over 5 min. 
DCL blank equilibrium; aniline catalysis of reversible hydrazone formation: The four bishydrazide 
linkers L1–L4 (4×2.4 μL, 10 mm, DMSO), aldehyde A1 (2.4 μL, 10 mm, water), aldehydes A2-A3 (2×2.4 
μL, 10 mm, DMSO) and aniline (15 μL, 0.1 m, DMSO) were added to a mixture of DMSO (15.6 μL, 15 % by 
vol.) and ammonium acetate buffer (252.6 μL, 100 mm, pH 6.4). The DCL was allowed to incubate at room 
temperature with occasional shaking, and was monitored periodically by HPLC to establish the blank 
composition until the relative populations of the hydrazones became constant. 
Enzyme-templated DCL assay: Protein, GST (to a final concentration of 20 μm, for mGSTM1-1; 152.8 μL, 
1.1 mg mL−1, in potassium phosphate buffer 0.1 m, pH 6.8) or BSA (to a final concentration of 20 μm, 199.5 
μL, 2.0 mg mL−1, in 0.9 % aqueous NaCl solution containing sodium azide), the four hydrazide linkers L1–L4 
(4×2.4 μL, 10 mm, DMSO), aldehyde A1 (2.4 μL, 10 mm, water), aldehydes A2-A3 (2×2.4 μL, 10 mm, 
DMSO) and aniline (15 μL, 0.1 m, DMSO) were added to a mixture of DMSO (15.6 μL, 15 % by vol.) and 
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ammonium acetate buffer (to a total volume of 255 μL, for mGSTM1-1; 99.8 μL, 100 mm, pH 6.4). The DCL 
was allowed to incubate at room temperature, with occasional shaking, for 48 h. HPLC analysis was 
performed and the traces were compared with the blank equilibrium. 
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